



SUGGESTED FORMULA

Phenytoin 5%, Nifedipine 2%, Misoprostol 0.0024%, Tobramycin Sulfate 5%, Metronidazole 2%
Cream

Version number: 1.0

Volume or quantity: 100 gm

Phenytoin, USP (PH161) HD	5 g
Nifedipine, USP (N1061)	2 g
Misoprostol (commercial tablets) HD*	2.4 mg (12 x 200 mcg tablets)
Metronidazole, USP (M1511)	2 g
Tobramycin Sulfate, USP (T1598)	5 g
Propylene Glycol, USP (PR130)	10 mL
Base, Hormone Cream-Heavy (B1309)	Q.S. 100gm

SUGGESTED COMPOUNDING PROCEDURES

Weigh all ingredients

1. Triturate the powders to a fine consistency
2. Crush Misoprostol tablets and triturate to fine powder
3. Add Propylene glycol and mix to form a paste
4. Geometrically incorporate step 3 into the Base and mix until uniform
5. Use an Electronic Mortar and Pestle and/or ointment mill to mix and reduce particle size
6. Transfer to appropriate container – click jar, syringe, tube or jar
7. Suggested Quality assessments:
 - a. color
 - b. texture
 - c. container
 - d. Label - auxiliary labels, storage, BUD, compounded medication

Store in air-tight container, at Controlled room temperature.

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates from reference books, peer-reviewed literature, intended duration of therapy, formulation from commercially available products,

organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date estimated to be 30 days.

Hazardous Drug (HD) Precautions:

Hazardous drugs should be handled according to USP <800>, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a primary engineering control (PEC) that meets USP Chapter <800> standards. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

***Warning - Do not use in pregnant patients; use proper precautions when handling this material.**

10/18rd